FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
12 letters match. Newest first.
-
DrugsCenter For Immunology Science, LLC
FDA cites Center for Immunology Science for a clinical trial of heat-killed Mycobacterium smegmatis without an Investigational New Drug application.
High risk -
DrugsProdrome Sciences USA, LLC
Prodrome Sciences studied its supplement ProdromeNeuro Oil as a dementia drug in 29 people without first filing an IND, FDA says.
High risk -
DrugsPamela K. Den Besten, DDS, MS
FDA warned sponsor-investigator Pamela K. Den Besten for running a pediatric dental gel study without an IND, enrolling 43 subjects.
High risk -
BiologicsMG Infusions
FDA warned MG Infusions it sells unlicensed fecal transplant products online without required approval.
High risk -
DrugsRichard W. Foltin, Ph.D.
FDA warned sponsor Dr. Richard W. Foltin for starting drug trials in people without an IND.
High risk -
DrugsRandy J. Epstein, M.D./Chicago Cornea Consultants, Ltd.
FDA warns Dr. Epstein/Chicago Cornea Consultants over trial without IND and inadequate drug records.
High risk -
DrugsTyrone L. McCall, M.D./Cornea Associates of Texas
FDA warns Dallas eye practice Cornea Associates for running a 69-subject drug study without an IND.
High risk -
DrugsMaggie Jeffries, M.D. / Avanti Anesthesiology, LLC
FDA warns Houston clinical investigator Dr. Maggie Jeffries for running drug trials without an IND and with informed-consent failures.
High risk -
DrugsDaniel Fred Goodman, M.D./Goodman Eye Center
FDA warns Dr. Daniel Fred Goodman/Goodman Eye Center over clinical drug study without required FDA application and missing consent/assent.
High risk -
DrugsLauren R. Klein, MD, M.S.
FDA cited Dr. Lauren R. Klein for running two emergency department drug studies without required investigational new drug applications.
High risk -
DrugsRAAS Nutritionals, LLC/Rare Antibody Antigen Supply, Inc.
FDA says RAAS Nutritionals ran human drug studies without required IND applications, despite claiming products were dietary supplements.
High risk -
DrugsKDunn and Associates, P.A. dba HealthQuilt
Houston research sponsor ran a COVID-19 drug study on people without an FDA-approved application or proper consent forms.
High risk